Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Cited In for PubMed (Select 15751079)

1.

Drugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birth.

Ng PY, Ireland DJ, Keelan JA.

Front Immunol. 2015 Apr 20;6:166. doi: 10.3389/fimmu.2015.00166. eCollection 2015. Review.

2.

Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts.

Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ.

ACS Med Chem Lett. 2014 Jan 23;5(4):446-50. doi: 10.1021/ml400485g. eCollection 2014 Apr 10.

3.

A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.

Habineza Ndikuyeze G, Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Flood P, Krick E, Propert KJ, Mason NJ.

PLoS One. 2014 May 5;9(5):e95404. doi: 10.1371/journal.pone.0095404. eCollection 2014.

4.

Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice.

Xin W, Huang C, Zhang X, Xin S, Zhou Y, Ma X, Zhang D, Li Y, Zhou S, Zhang D, Zhang T, Du G.

Br J Pharmacol. 2014 Jul;171(14):3526-38. doi: 10.1111/bph.12715.

PMID:
24712652
5.

Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.

Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K.

Front Oncol. 2013 May 16;3:120. doi: 10.3389/fonc.2013.00120. eCollection 2013.

6.

NF-κB as potential target in the treatment of melanoma.

Madonna G, Ullman CD, Gentilcore G, Palmieri G, Ascierto PA.

J Transl Med. 2012 Mar 20;10:53. doi: 10.1186/1479-5876-10-53. Review.

7.

Inhibitory kappa B Kinases as targets for pharmacological regulation.

Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A.

Br J Pharmacol. 2012 Feb;165(4):802-19. doi: 10.1111/j.1476-5381.2011.01608.x. Review.

8.

Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology.

Reay DP, Yang M, Watchko JF, Daood M, O'Day TL, Rehman KK, Guttridge DC, Robbins PD, Clemens PR.

Neurobiol Dis. 2011 Sep;43(3):598-608. doi: 10.1016/j.nbd.2011.05.008. Epub 2011 May 23.

9.

NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.

Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason NJ.

Clin Cancer Res. 2011 Jul 15;17(14):4661-71. doi: 10.1158/1078-0432.CCR-10-3310. Epub 2011 May 24.

10.

Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease.

Flood PM, Qian L, Peterson LJ, Zhang F, Shi JS, Gao HM, Hong JS.

Parkinsons Dis. 2011;2011:216298. doi: 10.4061/2011/216298. Epub 2011 Mar 30.

11.

Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy.

Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfín DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, Flood P, Kaumaya P, Freitas M, Kornegay JN, Mendell JR, Rafael-Fortney JA, Guttridge DC, Janssen PM.

Mol Med. 2011 May-Jun;17(5-6):508-15. doi: 10.2119/molmed.2010.00263. Epub 2011 Jan 20.

12.

Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ.

Cancer Res. 2010 May 1;70(9):3618-27. doi: 10.1158/0008-5472.CAN-09-2664.

13.

Akt1 is critical for acute inflammation and histamine-mediated vascular leakage.

Di Lorenzo A, Fernández-Hernando C, Cirino G, Sessa WC.

Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14552-7. doi: 10.1073/pnas.0904073106. Epub 2009 Jul 21.

14.

Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice.

Luong MX, Tam J, Lin Q, Hagendoorn J, Moore KJ, Padera TP, Seed B, Fukumura D, Kucherlapati R, Jain RK.

J Cell Physiol. 2009 May;219(2):430-7. doi: 10.1002/jcp.21686.

15.

Cell penetrating peptide inhibitors of nuclear factor-kappa B.

Orange JS, May MJ.

Cell Mol Life Sci. 2008 Nov;65(22):3564-91. doi: 10.1007/s00018-008-8222-z. Review.

16.

Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide.

Davé SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, Sepulveda AR, Jobin C, Baldwin AS, Robbins PD, Plevy SE.

J Immunol. 2007 Dec 1;179(11):7852-9.

17.

Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy.

Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC.

J Clin Invest. 2007 Apr;117(4):889-901. Epub 2007 Mar 22.

18.

Use of cell permeable NBD peptides for suppression of inflammation.

Strickland I, Ghosh S.

Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii75-82. Review.

19.

Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation.

Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP.

Arthritis Res Ther. 2006;8(4):R86.

20.

Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.

Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.

Arthritis Res Ther. 2005;7(6):R1348-59. Epub 2005 Sep 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk